Popular terms

Quinoline topics
Isoquinolin
Praziquantel
Carbon Atoms
Crystallin
Quinoline Derivatives
Pharmaceutically Acceptable Salt
Alkyl Group
Cycloalkyl
Pharmaceutically Acceptable Salts
Immunodeficiency
Retrovirus
Viral Infection
Human Immunodeficiency Virus
Angiogenesis
Sulfonamide

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Quinoline patents



      

This page is updated frequently with new Quinoline-related patent applications.




Date/App# patent app List of recent Quinoline-related patents
02/04/16
20160030416 
 Methods of treating b2-bradykinin receptor mediated angioedema patent thumbnailMethods of treating b2-bradykinin receptor mediated angioedema
Methods of treating b2-bradykinin receptor mediated angioedema in a subject by administering a composition containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate thereof. Oral formulations containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate thereof for the treatment of b2-bradykinin receptor mediated angioedema.
Shire Human Genetic Therapies, Inc.


02/04/16
20160030414 
 Benzoquinoline inhibitors of vmat 2 patent thumbnailBenzoquinoline inhibitors of vmat 2
The present invention relates to new benzoquinolone inhibitors of vmat2, pharmaceutical compositions thereof, and methods of use thereof.. .
Auspex Pharmaceuticals, Inc.


01/28/16
20160022675 
 Processes for preparing tetrahydroisoquinolines patent thumbnailProcesses for preparing tetrahydroisoquinolines
Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and compositions comprising the tetrahydroisoquinolines and other compounds, e.g, intermediates and by-products of the processes described herein. Pharmaceutical compositions comprising tetrahydroisoquinolines, methods of using tetrahydroisoquinolines in the treatment of depression are also disclosed..
Bristol-myers Squibb Company


01/21/16
20160016954 
 Tricyclic quinoline and quinoxaline derivatives patent thumbnailTricyclic quinoline and quinoxaline derivatives
The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-ht2c receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-ht2c receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-ht2c receptor.. .
Abbvie Deutschland Gmbh & Co. Kg


01/21/16
20160016951 
 Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors patent thumbnailNovel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
The present invention relates to naphthyridine and isoquinoline compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cdk8/19, and for the treatment of cdk8/19-related disorders.. .
Cancer Research Technology, Ltd.


01/21/16
20160016933 
 Isoquinolines as potassium ion channel inhibitors patent thumbnailIsoquinolines as potassium ion channel inhibitors
A compound of formula (i) (i) wherein a, r1, r1a, r3 and r24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, ikur-associated disorders, and other disorders mediated by ion channel function..
Bristol-myers Squibb Company


01/21/16
20160016908 
 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors patent thumbnail2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.. .
Glaxosmithkline Intellectual Property (no.2) Limited


01/14/16
20160009653 
 Cyanoisoquinoline compounds and methods of use thereof patent thumbnailCyanoisoquinoline compounds and methods of use thereof
The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoictin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:.
Fibrogen, Inc.


01/07/16
20160002207 
 New dihydroquinoline-2-one derivatives patent thumbnailNew dihydroquinoline-2-one derivatives
Wherein r1, r2, r3, r4, r5, r6, r7, r9, r10, r11 and a are as described herein, compositions including the compounds and methods of using the compounds.. .

01/07/16
20160002170 
 Crystalline forms of -acetic acid patent thumbnailCrystalline forms of -acetic acid
The present disclosure relates to crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid (compound a), the process of preparing crystalline forms of compound a, the pharmaceutical compositions containing them, and the methods of use thereof.. .
Fibrogen, Inc.


01/07/16
20160002168 

Use of quinoline derivatives for improving plant yield


Compounds (a) can be used for increasing the yield of useful plants or crop plants with respect to their harvested plant organs, wherein the compound (a) is selected from compounds of the formula (i) and hydrates or salts thereof,. .
Bayer Cropscience Ag


12/31/15
20150376186 

Quinoline derivatives as pde10a enzyme inhibitors


The present invention provides quinoline derivatives of formula i that are pde10a enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for pde10 over other pde subtypes.
H. Lundbeck A/s


12/31/15
20150376180 

Dihydroquinoline-2-one derivatives


Wherein r1, r2, r3, r4, r5, r6, r7, r9, r10 and r11 are as described herein, compositions including the compounds and methods of using the compounds.. .

12/31/15
20150376133 

C-met modulators and methods of use


The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-met, kdr, c-kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
Exelixis, Inc.


12/31/15
20150376132 

Quinoline sulfonyl derivatives and uses thereof


The present disclosure relates to quinoline sulfonyl compounds, compositions comprising these compounds and their use, in particular for the treatment of cancer. In particular, the present disclosure includes compounds of formula (i), and compositions and uses thereof:.
Advanced Medical Research Institute Of Canada


12/24/15
20150366877 

Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors


Methods of inhibiting replication of human cytomegalovirus (hcmv) are disclosed. In various configurations, these methods comprise administering a therapeutically effective amount of a bromodomain inhibitor to a subject in need thereof.
Washington University


12/17/15
20150364702 

Iridium complex and organic light-emitting device including the same


The present invention provides a novel iridium complex and an organic light-emitting device including the novel iridium complex. The novel iridium complex includes three ligands, and two of them have a phenyl-naphtho[2,1-f]isoquinoline skeleton.
Canon Kabushiki Kaisha


12/17/15
20150361044 

Stable crystal of 4-oxoquinoline compound


Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(s)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound a). A crystal of compound a, which shows a particular x-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2θ(°) as measured by x-ray powder diffractometry..
Japan Tobacco Inc.


12/10/15
20150353498 

Substituted isoquinolines as crth2 receptor modulators


The invention provides certain substituted isoquinolines of the formula (i), and their pharmaceutically acceptable salts and esters. The invention also provides pharmaceutical compositions comprising for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of crth2 function..
Merck Sharp & Dohme Corp.


12/10/15
20150353497 

Novel quinoline derivatives and their use in neurodegenerative diseases


The present invention relates to quinoline compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of p2x7, and for the treatment of p2x7-related disorders.. .
Merck Patent Gmbh


12/10/15
20150352098 

Substituted pyrano and furanoquinolines, their preparation and use as medicaments


The present invention relates to new substituted pyrano and furanoquinolines having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.. .
Laboratorios Del Dr. Esteve S.a.


12/03/15
20150344522 

Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof


The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.. .

12/03/15
20150344491 

[1,3] dioxolo [4,5-g] quinoline-6(5h)thione derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer


The present invention relates generally to methods, compounds and/or compositions suitable for inhibiting, preventing and/or treating cancer, e.g. Hepatocellular carcionoma (hcc).
Trustees Of Boston University


12/03/15
20150344434 

Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof


Described herein are compounds of formula (a), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity.
Epizyme, Inc.


12/03/15
20150344433 

Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof


Described herein are compounds of formula (a), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity.
Epizyme, Inc.


12/03/15
20150342945 

Substituted quinoline compounds and methods of use


The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans..
Sunshine Lake Pharma Co., Ltd.


11/26/15
20150336947 

Pyrroloquinoline alkaloids as antimalarial agents and process for the preparation thereof


The patent provides novel compounds with potential anti-malarial activity and process of synthesis thereof. Further, the process for the synthesis of known antimalarial natural products marinoquinazolinone a-f, aplidiopsamine a and their potential antimalarial analogues is disclosed..
Council Of Scientific & Industrial Research


11/26/15
20150336945 

Quinoline and quinazoline amides as modulators of sodium channels


The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.. .

11/26/15
20150336897 

Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors


The present invention is directed to novel quinoline compounds useful as s-nitrosoglutathione reductase (gsnor) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.. .
Nivalis Therapeutics, Inc.


11/26/15
20150335646 

Pyrimido[4,5-b]quinoline-4,5(3h,10h)-diones


The invention relates to compound of the formula (i); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.. .
Novartis Ag


11/26/15
20150335636 

Novel substituted imidazoquinolines


Imidazoquinolines of formula i that contain substituted amine or amide functionality at 1-position and that are effective as toll like receptor 7 activators are disclosed. These compounds are useful as anticancer agents..
4sc Ag


11/26/15
20150335635 

8-hydroxy quinoline derivatives


Or pharmaceutically acceptable salts, hydrates, or solvates thereof.. .

11/26/15
20150335634 

Isoquinoline alkaloid derivative for activating amp-dependent protein kinase


The present invention provides a method for activating the amp-dependent protein kinase (ampk) in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general formula i, preferably salsolinol or reticuline. The pharmaceutical composition is able to activate ampk, and thus is effective in the regulation of cell growth and metabolism, and the treatment of ampk associated diseases..
Zih Yuan Tang Biotechnology Co., Ltd


11/19/15
20150333279 

Organic light-emitting element and display apparatus


Provided is an organic light-emitting element having high luminous efficiency and a long lifetime. The organic light-emitting element includes a pair of electrodes and an organic compound layer placed between the pair of electrodes, in which the organic compound layer includes an iridium complex having a benzo[f]isoquinoline of a specific structure as a ligand and a metal complex compound of a specific structure..
Canon Kabushiki Kaisha


11/19/15
20150329498 

Irak inhibitors and uses thereof


The present invention provides quinazoline and quinoline compounds, compositions thereof, and methods of using the same. Also disclosed is the activity of such compounds as inhibitors of irak enzymes..
Nimbus Iris, Inc.


11/19/15
20150328207 

Benzoquinoline inhibitors of vesicular monoamine transporter 2


The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (vmat2), pharmaceutical compositions thereof, and methods of use thereof.. .
Auspex Pharmaceuticals, Inc.


11/12/15
20150322015 

Crystalline forms of a prolyl hydroxylase inhibitor


The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. .
Fibrogen, Inc.


11/12/15
20150320742 

Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline


C) paediatric disorders e.g. Autism, mental retardation and learning disabilities..

11/05/15
20150315200 

Substituted tetrahydroisoquinoline compounds as factor xia inhibitors


Or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..

11/05/15
20150315184 

4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor


Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.. .
Glaxosmithkline Llc


10/29/15
20150307490 

Process for the preparation of moxifloxacin hydrochloride


The present invention relates to an improved and industriously advantageous process by means of providing coupling/condensing of wet mass of (1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylic acid-o3,o4)bis(acyloxy-o)borate with (s,s)-2,8-diazabicyclo[4.3.0]nonane to give 1-cyclopropyl-7-[s,s]-2,8-diazabicyclo-[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride (moxifloxacin hydrochloride) of formula-i with high purity.. .
Mankind Research Centre


10/29/15
20150307453 

Novel quinoline derivatives and their applications


The invention relates to a series of quinoline derivatives of general formula i, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof m, r1, r2, x, y and n are defined as claims.
Shenyang Pharmaceutical University


10/22/15
20150303386 

Organic light-emitting device and display apparatus


Provided is an organic light-emitting device improved in emission efficiency and lifetime. The organic light-emitting device includes a pair of electrodes and an organic compound layer disposed between the pair of electrodes, in which: the organic compound layer includes a benzo[f]isoquinoline iridium complex of a specific structure and a hydrocarbon compound of a specific structure; and the hydrocarbon compound is a compound formed only of an sp2 carbon atom and a hydrogen atom..
Canon Kabushiki Kaisha


10/22/15
20150299246 

N-substituted indenoisoquinolines and syntheses thereof


N-substituted indenoisoquinoline compounds, and pharmaceutical formulations of n-substituted indenoisoquinoline compounds are described. Also described are processes for preparing n-substituted indenoisoquinoline compounds.
The Government Of The Usa As Represented By The Secretary Of The Dept Of Health And Human Services


10/22/15
20150299194 

4-amino-imidazoquinoline compounds


Wherein r1 to r4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer or infectious diseases..

10/22/15
20150299159 

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds


Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents.
Aerie Pharmaceuticals, Inc.


10/22/15
20150299104 

Method for producing 4-oxoquinoline compound


Wherein r is a fluorine atom or a methoxy group, and r400 is a hydrogen atom or a c1-c4 alkyl group, or a salt thereof, and a production method thereof, and a production method of an anti-hiv agent using the synthetic intermediate.. .

10/22/15
20150296779 

Substituted dihydropyridines for somatic embryogenesis in plants


Cyclopentyl 2,7,7-trimethyl-5-oxo-4-(4-pyridinyl)-1,4,5,6,7,8-hexahydro-3-quinolinecarboxylate and similar compounds are potentiators of auxin-induced somatic embryogenesis in plants. In particular, the inventors have discovered certain of these compounds induce somatic embryogenesis in arabidopsis in the presence of 2,4-d.
Stichting Dienst Landbouwkundig Onderzoek


10/15/15
20150295188 

Organic light-emitting element


Provided is an organic light-emitting element improved in luminous efficiency and lifetime. The organic light-emitting element includes a pair of electrodes and an organic compound layer placed between the pair of electrodes, in which the organic compound layer includes an iridium complex having a benzo[f]isoquinoline of a specific structure as a ligand and a heterocycle-containing compound of a specific structure..

10/15/15
20150291583 

Crystalline forms of pyrroloquinoline quinone disodium salt


The present invention relates to crystalline forms of pyrroloquinoline quinone disodium salt. The present invention provides crystalline form a and crystalline form b of pyrroloquinoline quinone disodium salt, and the methods and uses for the preparation thereof.

10/15/15
20150291532 

Amorphous form of quinoline derivative, and producing same


The invention provides an amorphous form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.. .

10/15/15
20150290232 

Drug composition for treating tumors and application thereof


The present invention belongs to the field of medicine and pharmaceutical chemistry, specifically relates to novel antitumor pharmaceutical combination, and particularly relates to pharmaceutical combination of bisbenzylisoquinoline alkaloids (e.g. Berbamine and tetrandrine) and anthracene compounds (e.g.

10/08/15
20150284361 

7--6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal


Disclosed is a technique for improving the water solubility and storage stability of 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound (1)) that is safe and not only has a strong antibacterial action but also is effective for resistant bacteria for which conventional antibacterial agent are less effective. Crystals of the hydrochloride salt of the compound (1), crystals of the hydrochloride salt hydrate of the compound (1), and crystals of the methanesulfonate salt of the compound (1) are provided.

10/08/15
20150284332 

The synthesis of tetrahydroisoquinolines from 2-methyl-1-phenyl substituted indenes


A procedure for the synthesis of tetrahydroisoquinolines from 2-methyl-1-phenyl substituted indene is described. The process involves the use of osmium tetroxide to cleave the indene double bond forming the keto aldehyde product, which is then combined with a substituted amine forming the substituted isoquinoline.

10/01/15
20150274713 

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin


With r1, r2, r3, r4, r5, r6, r7, r8, and r14 defined herein.. .

10/01/15
20150274671 

Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors


The present invention provides compounds of formula (i): (formula (i)) or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..
Bristol-myers Squibb Company


10/01/15
20150272881 

Reduced pyrroloquinoline quinone gel


An object of the present invention is to provide a gel comprising a reduced pyrroloquinoline quinone derivative or a salt thereof and a method for producing the same in a simple way and with high efficiency. According to the present invention, there is provided a gel comprising a reduced pyrroloquinoline quinone derivative or a salt thereof by mixing an oxidized pyrroloquinoline quinone derivative or a salt thereof, a dispersant, and a reducing agent at 50° c.
Mitsubishi Gas Chemical Company, Inc.


09/24/15
20150267233 

Compositions and methods for producing benzylisoquinoline alkaloids


The present invention relates to host cells that produce compounds that are characterized as benzylisoquinolines, as well as select precursors and intermediates thereof. The host cells comprise one, two or more heterologous coding sequences wherein each of the heterologous coding sequences encodes an enzyme involved in the metabolic pathway of a benzylisoquinoline, or its precursors or intermediates from a starting compound.
California Institute Of Technology


09/24/15
20150266901 

Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines


Thiazoloquinolines and thiazolonaphthyridines with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.. .
3m Innovative Properties Company


09/24/15
20150266887 

Method for producing nitrogen-containing heterocyclic n-oxide compound


The problem of the present invention is to provide a production method for safely synthesizing a nitrogen-containing heterocyclic n-oxide compound in high yield. Another problem of the present invention is to provide a novel n-oxide compound.
Nissan Chemical Industries, Ltd.


09/24/15
20150266855 

Crystalline forms of a factor xia inhibitor


The instant invention provides crystalline forms of (s,e)-4-(2-(3-(3-chloro-2-fluoro-6-(1h-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.. .
Bristol-myers Squibb Company


09/17/15
20150259358 

Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors


The present invention provides compounds of formula (i): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..
Bristol-myers Squibb Company


09/17/15
20150259346 

Hexahydrodiazepinoquinolines carrying a substituted alkyl radical


The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-ht2c receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-ht2c receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-ht2c receptor, and processes for preparing such compounds and compositions.. .
Abbvie Deutschland Gmbh & Co. Kg


09/17/15
20150259343 

Hexahydrodiazepinoquinolines carrying a cyclic radical


The present invention relates to tricyclic hexahydrodiazepinoquinolines carrying a cyclic substituent, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-ht2c receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-ht2c receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of 5-ht2c receptor, and processes for preparing such compounds and compositions.. .
Abbvie Deutschland Gmbh & Co. Kg


09/10/15
20150252039 

Process for the preparation of pyrido[2,1-a] isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine


Wherein r2, r3, r4 and prot are as defined in the specification.. .

09/10/15
20150252002 

Tetrahydroquinoline derivatives and their use as epac inhibitors


The invention relates to tetrahydroquinoline derivatives and their use in the treatment and/or the prevention of a disease wherein the epac protein is involved, such as inflammation, cancer, vascular diseases, kidney diseases, cognitive disorders and cardiac diseases.. .
Universite D'orleans


09/03/15
20150247863 

Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings


The present invention describes novel dyes, including coumarins, rhodamines, and rhodols that incorporate additional fused aromatic rings. The dyes of the invention absorb at a longer wavelength than structurally similar dyes that do not possess the fused aromatic rings.
Life Technologies Corporation


09/03/15
20150246091 

Compounds and methods for preventing or treating a viral infection


A compound is provided which has a structure i: a-b-c and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which a is a quinoline or quinoline-like group, b is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and c is an o-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be q-vd-oph (n-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxyl)methyl ketone), optionally in an o-methylated form.
UniversitÈ Paris-sud


09/03/15
20150246031 

Pharmaceutical composition and administrations thereof


The present invention relates to pharmaceutical compositions containing a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.. .
Vertex Pharmaceuticals Incorporated


08/27/15
20150239845 

Quinoline derivatives useful as cb-1 inverse agonists


The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the cb-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the cb-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders..
Janssen Pharmaceutica Nv


08/27/15
20150239844 

Quinoline derivatives useful as cb-1 inverse agonists


The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the cb-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the cb-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders..
Janssen Pharmaceutica Nv


08/27/15
20150238488 

Drug composition for treating tumors and application thereof


The present invention belongs to the field of medicine and pharmaceutical chemistry, specifically relates to novel antitumor pharmaceutical combinations, and particularly relates to pharmaceutical combinations of bisbenzylisoquinoline alkaloids (e.g. Berbamine and tetrandrine) and imatinib mesylates and their use in treating tumors..
Hangzhou Bensheng Pharmaceutical Co., Ltd.


08/20/15
20150232445 

Tetrahydroquinoline compositions as bet bromodomain inhibitors


Wherein w, x, y, z, r1, r2, r5, and r8 are as described herein.. .

08/20/15
20150231237 

Methods and products for treating proliferative diseases


Methods and products for treating proliferative diseases, and wounds, using as a pharmacon an autophagy inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In some embodiments, the invention combines a 4-aminoquinoline, exemplified by chloroquine, with a glycolytic inhibitor, exemplified by 2-deoxy-d-glucose and anti-vegf antibodies.
The Regents Of The University Of Colorado, A Body Corporate


08/20/15
20150231128 

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions


The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.. .
Allergan, Inc.


08/13/15
20150225348 

Process for preparing (1s)-1-phenyl-3,4-dihydro-2(1h)-isoquinoline-carboxylate


In formula i and ii, r is an alkyl or a substituted alkyl; lg is a leaving group.. .

08/06/15
20150218207 

N-substituted indenoisoquinolines and syntheses thereof


N-substituted indenoisoquinoline compounds, and pharmaceutical formulations of n-substituted indenoisoquinoline compounds are described. Also described are processes for preparing n-substituted indenoisoquinoline compounds.
The Government Of The United States Of America As Represented By The Secretary Of The Department Of


08/06/15
20150218162 

Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines


Imidazo-quinoline, -pyridine, and -naphthyridine ring systems (particularly quinolines, tetrahydroquinolines, pyridines, [1,5]naphthyridines, [1,5]tetrahydronaphthyridines) substituted at the 1-position with a cyclic substituent, pharmaceutical compositions containing the compounds, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.. .
3m Innovative Properties Company


08/06/15
20150218102 

6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and use


And pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein r1, r2, and r3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., nav1.7 and/or nav1.8. Methods for making the compounds are disclosed.

08/06/15
20150216866 

Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors


The present invention provides a method for treating or preventing a condition or disease in a human or an animal subject wherein the condition or disease is associated with lipoprotein metabolism, the method comprising administering to the subject a composition comprising benzylamine compounds.. .
Dr. Reddy's Laboratories Ltd.


08/06/15
20150216181 

Pesticide having an insecticide, acaricide and nematicide action based on isoquinoline alkaloids and flavonoids


The present invention relates to a pesticide having an insecticide, acaricide and nematicide action obtained from plant extracts that have important synergic interactions in their pesticide activity, the characteristics of which are efficient control of insects, mites and nematodes; low toxicity for mammals and low persistence in the environment. This pesticide is a composition based on plant extracts which is characterized because it is constituted by: isoquinoline alkaloids and their derivatives (0.1-20%) and flavonoids and their glycosylated derivatives (0.001-10%).
Promotora Tecnica Industrial, S.a. De C.v.


07/30/15
20150210711 

Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof


The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (i) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor.
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences


07/30/15
20150210644 

2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition


Various 2-aminoquinoline compounds as can be used, in vivo or in vitro, for selective inhibition of neuronal nitric oxide synthase.. .
Northwestern University


07/30/15
20150209364 

Method for treating epidermoid carcinoma


Disclosed herein is a method for enhancing the susceptibility of a subject having epidermoid carcinoma toward a tyrosine kinase inhibitor. The method includes administering to the subject an effective amount of a targeted therapy sensitizer and an effective amount of gefitinib.
Johnpro Biotech Inc.


07/30/15
20150209351 

Alpha adrenergic receptor modulators


Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzoimidazole or an isoquinoline as a core structure.
Allergan, Inc.




Quinoline topics: Isoquinolin, Praziquantel, Carbon Atoms, Crystallin, Quinoline Derivatives, Pharmaceutically Acceptable Salt, Alkyl Group, Cycloalkyl, Pharmaceutically Acceptable Salts, Immunodeficiency, Retrovirus, Viral Infection, Human Immunodeficiency Virus, Angiogenesis, Sulfonamide

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Quinoline for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Quinoline with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.3363

4773

1 - 1 - 102